RESUMO
A sputum eosinophilia is observed in 10-40% of COPD subjects. The blood eosinophil count is a biomarker of sputum eosinophilia, but whether it is associated with bronchial submucosal eosinophils is unclear. In 20 COPD subjects and 21 controls we assessed the number of bronchial submucosal eosinophils and reticular basement membrane thickening and found these were positively correlated with the blood eosinophil percentage. In COPD, blood eosinophils are a good biomarker of bronchial eosinophilia and remodelling.
Assuntos
Membrana Basal/patologia , Biomarcadores/sangue , Eosinófilos/patologia , Doença Pulmonar Obstrutiva Crônica/sangue , Doença Pulmonar Obstrutiva Crônica/diagnóstico , Adulto , Eosinofilia , Feminino , Humanos , Contagem de Leucócitos , MasculinoRESUMO
BACKGROUND: Eosinophilic airway inflammation is observed in 10-30% of COPD subjects. Whether increased eosinophils or impairment in their clearance by macrophages is associated with the severity and frequency of exacerbations is unknown. METHODS: We categorised 103 COPD subjects into 4 groups determined by the upper limit of normal for their cytoplasmic macrophage red hue (<6%), an indirect measure of macrophage efferocytosis of eosinophils, and area under the curve sputum eosinophil count (≥ 3%/year). Eosinophil efferocytosis by monocyte-derived macrophages was studied in 17 COPD subjects and 8 normal controls. RESULTS: There were no differences in baseline lung function, health status or exacerbation frequency between the groups: A-low red hue, high sputum eosinophils (n=10), B-high red hue, high sputum eosinophils (n=16), C-low red hue, low sputum eosinophils (n=19) and D- high red hue, low sputum eosinophils (n=58). Positive bacterial culture was lower in groups A (10%) and B (6%) compared to C (44%) and D (21%) (p=0.01). The fall in FEV1 from stable to exacerbation was greatest in group A (ΔFEV1 [95 % CI] -0.41 L [-0.65 to -0.17]) versus group B (-0.16 L [-0.32 to -0.011]), C (-0.11 L [-0.23 to -0.002]) and D (-0.16 L [-0.22 to -0.10]; p=0.02). Macrophage efferocytosis of eosinophils was impaired in COPD versus controls (86 [75 to 92]% versus 93 [88 to 96]%; p=0.028); was most marked in group A (71 [70 to 84]%; p=0.0295) and was inversely correlated with exacerbation frequency (r=-0.63; p=0.006). CONCLUSIONS: Macrophage efferocytosis of eosinophils is impaired in COPD and is related to the severity and frequency of COPD exacerbations.
Assuntos
Citofagocitose/fisiologia , Eosinofilia/fisiopatologia , Eosinófilos , Macrófagos/fisiologia , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Idoso , Cor , Progressão da Doença , Feminino , Volume Expiratório Forçado , Humanos , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Doença Pulmonar Obstrutiva Crônica/imunologia , Índice de Gravidade de Doença , Escarro/citologiaRESUMO
Chronic lung diseases are very common and form a major threat to large proportions of the population with increased morbidity and mortality. Asthma is one of the most common eosinophilic airway diseases. However, there is growing evidence that eosinophilic inflammation is also important in subgroups of patients with chronic obstructive pulmonary disease, chronic cough and idiopathic pulmonary fibrosis. Several studies have shown that sputum eosinophilia is associated with a favorable response to treatment of corticosteroids in both asthma and chronic obstructive pulmonary disease, and tailored strategies aimed to normalize sputum eosinophils have resulted in a significant reduction in exacerbation rates. In this article, the authors review the role of eosinophilic inflammation in the diagnosis and management of chronic respiratory diseases.